North American Report

Obesity Pipeline Therapies: Industry Analysis, Key Pharma Companies, Clinical Trials, Drug and Medicine by DelveInsight

 Breaking News
  • No posts were found

Obesity Pipeline Therapies: Industry Analysis, Key Pharma Companies, Clinical Trials, Drug and Medicine by DelveInsight

October 27
02:42 2021
Obesity Pipeline Therapies: Industry Analysis, Key Pharma Companies, Clinical Trials, Drug and Medicine by DelveInsight
Obesity Pipeline

DelveInsight’s Obesity Pipeline Insight report offers exhaustive global coverage of available pipeline therapies in different phases of clinical development, key companies working to advance the pipeline space, and future growth potential of the Obesity pipeline domain.

 

Some of the significant pointers taken from the Obesity Pipeline report:

  • DelveInsight’s analysis presents Obesity Pipeline with 80+ active players in the domain investigating 80+ pipeline therapies
  • Major companies such as ERX Pharmaceuticals, Amgen, Allysta Pharmaceuticals, Empros Pharma, Innovent Biologics, Pfizer, Boehringer Ingelheim, MedImmune LLC, Scohia Pharma, Eli Lilly and Company, and others are developing potential drug candidates to improve the Obesity treatment scenario. 
  • Key Obesity pipeline therapies such as ERX1000, AMG 171, ALY688-SR, EMP16-02, IBI362, PF-06882961, BI 456906, SCO-094, MEDI0382, Tirzepatide, and others are under investigation in different phases of clinical trials for the treatment of Obesity. 
  • In July 2021, AstraZeneca collaborated with Regeneron to foster research, develop and commercialize small molecule compounds directed against the GPR75 target with the potential to treat Obesity and related co-morbidities. 
  • In June 2021, Innovent Biologics announced that the first subject had been successfully dosed in Phase II clinical trial (NCT04904913) of IBI362, a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist in China. 
  • In April 2021, Boehringer Ingelheim and Zealand Pharma announced the initiation of two Phase II trials of the GLP-1/glucagon dual agonist BI 456906 for adults who are overweight or obese and for adults with non-alcoholic steatohepatitis (NASH). 

 

Request for Sample to know which pharma company is expected to be at the forefront in the coming years @ https://www.delveinsight.com/sample-request/obesity-pipeline-insight

 

The Obesity pipeline report lays down detailed profiles of the Obesity pipeline assets as well as the inactive and dormant Obesity drug assets, comparative analysis of clinical and non-clinical stage Obesity products, rich assessment of driving and restraining factors, along with the opportunities and risks in the Obesity pipeline landscape.

 

Obesity Overview

Obesity is a complex disorder that involves the accumulation of excessive amounts of fat in the body. It is a medical problem that is associated with the heightened risks of other health conditions such as diabetes, heart disease, cancers, high blood pressure, and other cardiovascular diseases. At present, Obesity has become a global concern causing the death of more than 4 million people each year.

 

Obesity Pipeline Drugs

Drug

Company

Phase

MoA

RoA

SCO-094  

Scohia Pharma

Phase I

Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide 1 receptor agonists

Oral

ERX1000

ERX Pharmaceuticals

Phase I

leptin sensitizer

Oral

AMG 171

Amgen

Phase I

Undefined mechanism

NA

ALY688-SR

Allysta Pharmaceuticals

Phase I

Adiponectin receptor agonists

Subcutaneous

EMP16-02

Empros  Pharma

Phase II

Alpha-glucosidase inhibitors; Amylase inhibitors; Lipase inhibitors

Oral

IBI362

Innovent Biologics

Phase II

Glucagon-like peptide 1 receptor agonists; Glucagon receptor agonists

Subcutaneous

BI 456906

Boehringer Ingelheim,

Phase II

Glucagon-like peptide 1 receptor agonists; Glucagon receptor agonists

Subcutaneous

MEDI0382

 MedImmune LLC, 

Phase II

Glucagon receptor agonists; Glucagon-like peptide 1 stimulants

Subcutaneous

Tirzepatide

Eli Lilly and Company

Phase III

Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide 1 receptor agonists

Subcutaneous

PF-06882961

Pfizer

Phase II

Glucagon-like peptide 1 receptor agonists

Oral

 

Discover more about the disease, therapies, and Obesity pipeline activity @ https://www.delveinsight.com/sample-request/obesity-pipeline-insight

 

Obesity Therapeutics Assessment

The Obesity Pipeline report proffers a comprehensive picture of the novel Obesity pipeline therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action. 

By Product Type

  • Mono
  • Combination
  • Mono/Combination

By Stage

  • Discovery 
  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Pre-registration

By Route of Administration

  • Subcutaneous
  • Oral

By Molecule Type 

  • Small molecules
  • Peptides
  • Lactones

By Mechanism of Action

  • Gastric inhibitory polypeptide receptor agonists
  • Glucagon-like peptide 1 receptor agonists
  • Adiponectin receptor agonists
  • Alpha-glucosidase inhibitors 
  • Amylase inhibitors
  • Lipase inhibitors

By Targets

  • Gastric inhibitory polypeptide receptor
  • Glucagon-like peptide 1 receptor
  • Adiponectin receptor
  • Alpha-glucosidase
  • Amylase
  • Lipase

 

Scope of the Obesity Pipeline Report 

  • Coverage: Global 
  • Major Players: ERX Pharmaceuticals, Amgen, Allysta Pharmaceuticals, Empros Pharma, Innovent Biologics, Pfizer, Boehringer Ingelheim, MedImmune LLC, Scohia PharmaEli Lilly and Company
  • Key Obesity Pipeline Therapies: ERX1000, AMG 171, ALY688-SR, EMP16-02, IBI362, PF-06882961, BI 456906, SCO-094, MEDI0382, Tirzepatide

 

For rich insights into emerging therapies and assessment, visit @ https://www.delveinsight.com/sample-request/obesity-pipeline-insight

 

Table of Contents 

1

Introduction

2

Executive Summary

3

Obesity: Overview

4

Pipeline Therapeutics

5

Late Stage Products (Phase III)

6

Mid Stage Products (Phase II)

7

Mid Stage Products (Phase II)

8

Early Stage Products (Phase I/II)

9

Early Stage Products (Phase I)

10

Preclinical and Discovery  Stage Products

11

Inactive Products

12

Therapeutic Assessment

13

Inactive Products

14

Obesity Key Companies

15

Obesity Key Products

16

Obesity- Unmet Needs

17

Obesity- Market Drivers and Barriers

18

Appendix

19

About DelveInsight

 

About Delveinsight: 

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/obesity-pipeline-insight